Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy.

MLA

Harrison, Claire N., et al. “Health-Related Quality of Life and Symptoms in Patients with Myelofibrosis Treated with Ruxolitinib versus Best Available Therapy.” British Journal of Haematology, vol. 162, no. 2, July 2013, pp. 229–39. EBSCOhost, https://doi.org/10.1111/bjh.12375.

APA

Harrison, C. N., Mesa, R. A., Kiladjian, J.-J., Al-Ali, H.-K., Gisslinger, H., Knoops, L., Squier, M., Sirulnik, A., Mendelson, E., Zhou, X., Copley-Merriman, C., Hunter, D. S., Levy, R. S., Cervantes, F., Passamonti, F., Barbui, T., Barosi, G., & Vannucchi, A. M. (2013). Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology, 162(2), 229–239. https://doi.org/10.1111/bjh.12375

Chicago

Harrison, Claire N, Ruben A Mesa, Jean-Jacques Kiladjian, Haifa-Kathrin Al-Ali, Heinz Gisslinger, Laurent Knoops, Margaret Squier, et al. 2013. “Health-Related Quality of Life and Symptoms in Patients with Myelofibrosis Treated with Ruxolitinib versus Best Available Therapy.” British Journal of Haematology 162 (2): 229–39. doi:10.1111/bjh.12375.